Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
A little goes a long way, so start with a pea-sized amount and adjust as needed
The first generation of GLP-1 therapies exhibit reduced susceptibility to enzymatic degradation, while providing effective glucose control, improved -cell function, body weight loss and decreased systolic blood pressure in patients with T2D (Meier, 2012) The newly developed incretin mimetics, including albiglutide, dulaglutide and semaglutide, are designed to have extended pharmacokinetic profiles and efficacy suitable once-weekly administration
Weight loss during this phase is modest, typically 1 to 3% of body weight over four weeks
About 1 in 8 adult Americans has already used GLP-1 drugs
US$ 24.46
US$ 22.19
US$ 28.57
US$ 23.39
US$ 21.76
US$ 25.17
US$ 29.16
US$ 21.79
US$ 21.18
US$ 23.20
